Association of serum uric acid and serum uric acid/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study

血清尿酸及血清尿酸/肌酐比值与青年人代谢功能障碍相关性脂肪肝疾病的关系:一项回顾性研究

阅读:1

Abstract

BACKGROUND: Metabolic dysfunction-associatedsteatotic liver disease (MASLD) has become the most prevalent chronic liver disease worldwide. Its incidence continues to rise with a marked trend toward younger age groups, posing dual challenges for early screening and standardized diagnosis and treatment. There is an urgent clinical need for simple-to-operate, highly sensitive serological markers to enable early disease identification. PURPOSE: This study aims to investigate the correlation between serum uric acid (SUA) and serum uric acid to creatinine ratio (SUA/Cr) levels in young adults and MASLD and its components. METHODS: A retrospective analysis was conducted on 5,224 individuals aged 20–45 years who underwent physical examinations at Northern Jiangsu People’s Hospital in 2019. Measured the patient’s body mass index(BMI), systolic blood pressure(SBP), diastolic blood pressure(DBP), fasting blood glucose(FBG), creatinine(Cr), triglycerides(TG), total cholesterol(TC), serum uric acid(SUA), high-density lipoprotein(HDL-c) and other indicators. Logistic regression analysis was employed to investigate the correlations among SUA, SUA/Cr, and the components of MASLD in the young adults while adjusting for confounding factors. The receiver operating characteristic (ROC) curve analysis was performed to evaluate discriminatory ability. RESULTS: The levels of SUA and SUA/Cr in the MASLD cohort were significantly higher than those in the non-MASLD cohort. Elevated SUA and SUA/Cr levels were associated with components for MASLD. Both SUA (OR: 1.014, 95% CI: 1.013–1.015) and SUA/Cr (OR: 2.570, 95% CI: 2.368–2.788) were significantly associated with MASLD (P < 0.001). The Area Under Curve(AUC) values were 0.807 and 0.724, respectively. CONCLUSION: SUA and SUA/Cr levels are significantly associated with MASLD and its components in young adults. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。